Biotech · Public company · Miami, FL, US
Summit Therapeutics Inc.
Ticker SMMT · SEC CIK 0001599298
Track this companyFree. Adds Summit Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline15
- AK112 InjectionPhase 3 · Non-Squamous Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Drug: Bevacizumab InjectionPhase 3 · Metastatic Colorectal Cancer (CRC)ClinicalTrials.gov · fetched Nov 12, 2026
- Drug: Ivonescimab InjectionPhase 3 · Metastatic Colorectal Cancer (CRC)ClinicalTrials.gov · fetched Nov 12, 2026
- enfortumab vedotin (EV)Phase 3 · Metastatic Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Ivonescimab Dose 1Phase 3 · Metastatic Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Ivonescimab Dose 2Phase 3 · Metastatic Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Ivonescimab InjectionPhase 3 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Ivonescimab RP3DPhase 3 · Metastatic Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Metastatic Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab InjectionPhase 3 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- IvonescimabPhase 2 · Renal Cell Carcinoma, Clear CellClinicalTrials.gov · fetched Nov 12, 2026
- Ivonescimab (dose level 1) combined with CadonilimabPhase 2 · Renal Cell Carcinoma, Clear CellClinicalTrials.gov · fetched Nov 12, 2026
- Ivonescimab (dose level 2) combined with CadonilimabPhase 2 · Renal Cell Carcinoma, Clear CellClinicalTrials.gov · fetched Nov 12, 2026
- Ivonescimab combined with IpilimumabPhase 2 · Renal Cell Carcinoma, Clear CellClinicalTrials.gov · fetched Nov 12, 2026
- Nivolumab combined with IpilimumabPhase 2 · Renal Cell Carcinoma, Clear CellClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)PHASE2 · NOT_YET_RECRUITING · started Feb 7, 2027ClinicalTrials.gov NCT07743138 · fetched Nov 12, 2026
- A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)PHASE2 · NOT_YET_RECRUITING · started Jan 16, 2027ClinicalTrials.gov NCT07753824 · fetched Nov 12, 2026
- A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal CancerPHASE2 · NOT_YET_RECRUITING · started Oct 19, 2026ClinicalTrials.gov NCT07877194 · fetched Nov 12, 2026
- A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial CarcinomaPHASE2_PHASE3 · RECRUITING · started Sep 10, 2026ClinicalTrials.gov NCT07815665 · fetched Nov 12, 2026
- A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerPHASE1 · RECRUITING · started May 27, 2026ClinicalTrials.gov NCT07619339 · fetched Nov 12, 2026
- Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLCPHASE2 · RECRUITING · started May 1, 2026ClinicalTrials.gov NCT07405190 · fetched Nov 12, 2026
- A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung CancerPHASE1_PHASE2 · RECRUITING · started Apr 10, 2026ClinicalTrials.gov NCT07535463 · fetched Nov 12, 2026
- A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerPHASE1_PHASE2 · RECRUITING · started Apr 9, 2026ClinicalTrials.gov NCT07535437 · fetched Nov 12, 2026
- A Study of Ivonescimab in People With LeiomyosarcomaPHASE2 · RECRUITING · started Apr 1, 2026ClinicalTrials.gov NCT07516925 · fetched Nov 12, 2026
- Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung CancerPHASE2 · RECRUITING · started Mar 30, 2026ClinicalTrials.gov NCT07057791 · fetched Nov 12, 2026
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsPHASE1_PHASE2 · RECRUITING · started Jan 30, 2026ClinicalTrials.gov NCT07397338 · fetched Nov 12, 2026
- Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck CancerPHASE2 · RECRUITING · started Nov 18, 2025ClinicalTrials.gov NCT07094685 · fetched Nov 12, 2026
- Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerPHASE3 · RECRUITING · started Nov 18, 2025ClinicalTrials.gov NCT07228832 · fetched Nov 12, 2026
- Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAPHASE2 · RECRUITING · started Oct 10, 2025ClinicalTrials.gov NCT07070466 · fetched Nov 12, 2026
- Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal CancerPHASE2 · RECRUITING · started Jul 28, 2025ClinicalTrials.gov NCT06959550 · fetched Nov 12, 2026
- Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast CancerPHASE2 · RECRUITING · started Jul 25, 2025ClinicalTrials.gov NCT07017673 · fetched Nov 12, 2026
- Ivonescimab for the Treatment of Thymic CancerPHASE2 · RECRUITING · started Jul 15, 2025ClinicalTrials.gov NCT06980077 · fetched Nov 12, 2026
- Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell CarcinomaPHASE2 · RECRUITING · started Jul 2, 2025ClinicalTrials.gov NCT06940518 · fetched Nov 12, 2026
- A Study of Ivonescimab in People With Endometrial and Cervical CancersPHASE2 · RECRUITING · started Apr 4, 2025ClinicalTrials.gov NCT06925724 · fetched Nov 12, 2026
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1PHASE3 · RECRUITING · started Feb 27, 2025ClinicalTrials.gov NCT06767514 · fetched Nov 12, 2026
- A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland CancersPHASE2 · RECRUITING · started Feb 26, 2025ClinicalTrials.gov NCT06805617 · fetched Nov 12, 2026
- A Phase I/II Study of IVONESCIMAB in Recurrent GlioblastomaPHASE1_PHASE2 · RECRUITING · started Jan 30, 2025ClinicalTrials.gov NCT06672575 · fetched Nov 12, 2026
- Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell CarcinomaPHASE2 · RECRUITING · started Dec 2, 2024ClinicalTrials.gov NCT06567314 · fetched Nov 12, 2026
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 26, 2023ClinicalTrials.gov NCT05899608 · fetched Nov 12, 2026
- Phase III Study of AK112 for NSCLC PatientsPHASE3 · ACTIVE_NOT_RECRUITING · started May 4, 2023ClinicalTrials.gov NCT06396065 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 23, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 23, 2026 · fetched Nov 12, 2026